**Core Concept**
Tumor lysis syndrome (TLS) is a life-threatening condition that occurs when a large number of cancer cells die rapidly, releasing their contents into the bloodstream. This can lead to hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury.

**Why the Correct Answer is Right**
Tumor lysis syndrome typically presents with hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. The correct option is the one that does not fit this profile. The mechanism behind TLS involves the breakdown of cancer cells, which releases intracellular contents, including potassium, phosphate, and nucleic acids into the bloodstream.

**Why Each Wrong Option is Incorrect**
**Option A:** Hypercalcemia - This is incorrect because TLS is typically associated with hypocalcemia, not hypercalcemia. Hypercalcemia is more commonly seen in conditions such as hyperparathyroidism or malignancy with lytic bone lesions.
**Option B:** Hyperuricemia - This is incorrect because TLS is typically associated with hyperuricemia, not hypouricemia. Hyperuricemia occurs due to the breakdown of nucleic acids from the lysed cancer cells.
**Option C:** Hypokalemia - This is incorrect because TLS is typically associated with hyperkalemia, not hypokalemia. Hyperkalemia occurs due to the release of potassium from the lysed cancer cells.
**Option D:** Metabolic acidosis - This is incorrect because TLS is typically associated with metabolic acidosis, not metabolic alkalosis. Metabolic acidosis occurs due to the accumulation of acidic byproducts from the breakdown of nucleic acids.

**Clinical Pearl / High-Yield Fact**
When managing TLS, it is essential to monitor electrolyte levels closely and administer medications such as allopurinol to prevent uric acid accumulation.

**Correct Answer:** D. Metabolic acidosis.